Kenneth Jaffe, MD
Geriatric Medicine · Atlantis, FLNPI 1174507529
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,193 of the $3,629 with a category attached, or 88.0%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $925 and has fallen 74.8% since, to $233 in 2025. Among geriatric medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$733
- AbbVie$403
- Otsuka America Pharmaceutical, Inc.$257
- Novo Nordisk$243
- Astellas Pharma US Inc$205
- Bayer$201
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$702%
- Food & beverage$3,19388%
- Education$36610%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $733 |
| AbbVie(2 entities) | 26 | $403 |
| Otsuka America Pharmaceutical, Inc. | 13 | $257 |
| Novo Nordisk | 28 | $243 |
| Astellas Pharma US Inc | 3 | $205 |
| Bayer | 8 | $201 |
| Pfizer | 9 | $151 |
| Eisai Inc. | 7 | $108 |
| GSK | 6 | $104 |
| Abbott | 5 | $102 |
| Exact Sciences | 4 | $97 |
| Orexo US, Inc. | 5 | $87 |
| Biogen | 4 | $84 |
| Johnson & Johnson | 4 | $77 |
| Indivior Inc. | 4 | $72 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| BD | 2 | $70 |
| Lilly USA, LLC | 4 | $68 |
| Novartis | 3 | $58 |
| Lundbeck LLC | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $43 |
| Merck | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Viiv Healthcare Company | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $23 |
| Amgen | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Acera Surgical, Inc. | 1 | $16 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $8 |
How this compares
$3,629 in reported general payments places this provider in the 90th percentile of 305 geriatric medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 80 | $60,812 |
| EliquisApixaban | 49 | $49,347 |
| RybelsusSemaglutide | 38 | $46,885 |
| OzempicSemaglutide | 34 | $44,739 |
| RexultiBrexpiprazole | 19 | $33,223 |
| XareltoRivaroxaban | 29 | $32,366 |
| Xtampza ErOxycodone Myristate | 19 | $28,615 |
| OxycontinOxycodone Hcl | 13 | $26,473 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $13,091 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 64 | $11,303 |
| Dexlansoprazole DrDexlansoprazole | 13 | $4,397 |
| Oxycodone Hcl | 137 | $3,558 |
| Rosuvastatin Calcium | 109 | $2,158 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 43 | $1,924 |
| Losartan Potassium | 140 | $1,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $243 | $91,62572 claims |
| AstraZenecaFarxiga | $733 | $60,81280 claims |
| PfizerEliquis | $151 | $49,34749 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $257 | $33,22319 claims |
| Johnson & JohnsonXarelto | $77 | $32,36629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 305 geriatric medicine providers in Florida.
Other geriatric medicine in Atlantis
- Malcolm FraserBrooksville$359K
- Andrew ScanameoTallahassee$172K
- Naushira PandyaDavie$145K
- Rosemary LairdViera$64K
- Jonathan AppelbaumMonticello$59K
- John PotomskiMelbourne$31K
- Valeria Baldivieso HurtadoWinter Park$28K
- Kae FerberNaples$18K
- Stuti DangMiami$17K
- Angel HerreraNaples$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.